UniQure Biopharma B.V.
8 clinical trials · Sponsor
◉ Watch UniQure Biopharma B.V.
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) (NCT06100276) | UniQure Biopharma B.V. | 2024-08-01 |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (NCT06063850) | UniQure Biopharma B.V. | 2024-06-12 |
| Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease (NCT06270316) | UniQure Biopharma B.V. | 2024-06-05 |
| Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease (NCT05243017) | UniQure Biopharma B.V. | 2021-10-07 |
| Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease (NCT04120493) | UniQure Biopharma B.V. | 2019-09-06 |
Track UniQure Biopharma B.V. automatically
Every clearance here is in the API, with alerts when new ones post.